TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2025. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 3, 2026
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of comprehensive income (loss)
| Year ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net income (loss) | $1,418 | $(1,959) | $(615) |
| Other comprehensive income (loss), net of tax: | |||
| Currency translation adjustment | 732 | (530) | 80 |
| Unrealized gain (loss) on derivative financial instruments, net | 39 | 28 | 29 |
| Unrealized gain (loss) on defined benefit plans, net | 13 | (6) | (18) |
| Total other comprehensive income (loss) | 784 | (508) | 91 |
| Total comprehensive income (loss) | 2,202 | (2,467) | (524) |
| Comprehensive income (loss) attributable to redeemable and non-redeemable non-controlling interests | 34 | (381) | (106) |
| Comprehensive income (loss) attributable to Teva | $2,168 | $(2,086) | $(418) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.